Nanomix Corporation announced that it has initiated a clinical validation study with Hospital Clinico San Carlos (HCSC) in Madrid, Spain to evaluate the performance of the Nanomix eLab® mobile immunoassay diagnostic system and the S1 Panel assay for the detection of critical infections such as sepsis in the emergency department. The principal investigator of the study is Dr. Juan González del Castillo, Internal Medicine Specialist, Assistant Physician of the Emergency Service of HCSC and Coordinator of the Infections Group of the Spanish Society of Emergency Medicine (SEMES). The Nanomix eLab® system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing.

The Nanomix eLab® system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. Furthermore, the S1 Panel Cartridge was developed as an aid in rapidly diagnosing critical infections including sepsis. The panel provides quantitative test results for procalcitonin (PCT), C-reactive protein (CRP) and lactate (LAC) from a single venous whole blood or plasma sample type.

The assay runs on the eLab Analyzer with results available in approximately 12 minutes from sample to answer, versus the current diagnostic solutions which can take hours to provide a test result. The S1 Panel assay has received the CE marking in Europe and has UK Medicines and Healthcare products Regulatory Agency (MHRA) registration.